Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome was a weighted score, but individual components of the outcome showed a difference favouring H-ISDN for all-cause mortality, first HHF, and change in quality of life score.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [79]
In the citing paper
“Digoxin may reduce the risk of HF hospitalization in patients with HFrEF treated with ACE-Is, irrespective of diabetes status.519”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [519]
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Self-citationSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Cited by
Items 301–400 of 1,001
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 67
Yancy, C. W., Benjamin, E. J., Fabunmi, R. P., & Bonow, R. O. (2005) · Circulation · doi:10.1161/01.cir.0000157740.93598.51 · Cited by 66
Self-citationMisreading race and genomics after BiDil
Kahn, J. (2005) · Nature Genetics · doi:10.1038/ng0705-655 · Cited by 62
“This is because A-HeFT enrolled only “self-identified” African Americans; there was no comparison populatio”
BackgroundRacial Differences in Nitric Oxide—Dependent Vasorelaxation
Mata‐Greenwood, E., & Chen, D. (2008) · Reproductive Sciences · doi:10.1177/1933719107312160 · Cited by 66
“In the past decade, a new drug combination of isosorbide dinitrate and hydralazine has consistently shown beneficial effects in AA patients with heart failure.(103) These clinical studies have clearly demonstrated that AAs can benefit greatly from NO donor therapy and that the smooth muscle response to exogenous NO is…”
BackgroundGodo, S., Sawada, A., Saito, H., Ikeda, S., Enkhjargal, B., Suzuki, K., Tanaka, S., & Shimokawa, H. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306499 · Cited by 62
cGMP Signaling and Modulation in Heart Failure
Blanton, R. M. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000749 · Cited by 62
Semler, M. W., Bernard, G. R., Aaron, S. D., Angus, D. C., Biros, M. H., Brower, R. G., Calfee, C. S., Colantuoni, E., Ferguson, N. D., Gong, M. N., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1595ws · Cited by 61
Heidenreich, P. A., Fonarow, G. C., Breathett, K. K., Jurgens, C. Y., Pisani, B., Pozehl, B., Spertus, J. A., Taylor, K. G., Thibodeau, J. T., Yancy, C. W., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000099 · Cited by 70
Self-citationCarson, P. E., Tam, S. W., Ghali, J. K., Archambault, W. T., Taylor, A. L., Cohn, J. N., Braman, V. M., Worcel, M., & Anand, I. S. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.05.016 · Cited by 61
Self-citationAspects of Nitric Oxide in Health and Disease: A Focus on Hypertension and Cardiovascular Disease
Giles, T. D. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.06023.x · Cited by 70
DeFilippis, E. M., Echols, M. R., Adamson, P. B., Batchelor, W., Cooper, L. B., Cooper, L. S., Desvigne-Nickens, P. M., George, R. T., Ibrahim, N. E., Jessup, M. L., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0161 · Cited by 61
Self-citationTargeting NOS as a therapeutic approach for heart failure
Tang, L., Wang, H., & Ziolo, M. T. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.013 · Cited by 64
Qaseem, A., Fihn, S. D., Dallas, P., Williams, S., Owens, D. K., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00011 · Cited by 60
Oral Levosimendan in Patients with Severe Chronic Heart Failure—The PERSIST Study
Nieminen, M. S., Cleland, J. G. F., Eha, J., Belenkov, Y. N., Kivikko, M., Põder, P., & Sarapohja, T. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.09.006 · Cited by 63
“The mean MLHFQoL score of 57–60 at baseline is similar to the mean of 59 reported in the MIRACLE study evaluating the effects of cardiac resynchronization therapy in advanced heart failure [15] and higher than the mean of 51 reported in A-HEFT study investigating the effects of hydralazine/ nitrate [14].”
ResultOxidative Stress and Heart Failure in Altered Thyroid States
Mishra, P., & Samanta, L. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/741861 · Cited by 65
“Hydralazine has been demonstrated to reduce mortality in heart failure [170] and has additional inhibitory effects on the generation of superoxide and peroxynitrite [171].”
BackgroundBhardwaj, A., Rehman, S., Mohammed, A. A., Baggish, A. L., Moore, S. A., & Januzzi, J. L. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.01.005 · Cited by 59
Dumaual, C. M., Miao, X., Daly, T. M., Bruckner, C., Njau, R., Fu, D., Close, S. L., Bauer, N. L., Watanabe, N., Hardenbol, P., et al. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.3.293 · Cited by 59
CSI position statement on management of heart failure in India
Guha, S., Harikrishnan, S., Ray, S., Sethi, R., Ramakrishnan, S., Banerjee, S., Bahl, V. K., Goswami, K. C., Banerjee, A. K., Shanmugasundaram, S., et al. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.05.003 · Cited by 65
Nitric Oxide in the Pathogenesis of Cardiac Disease
Raij, L. R. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.06025.x · Cited by 75
Parissis, J. T., Rafouli-Stergiou, P., Mebazaa, A., Ikonomidis, I., Bistola, V., Nikolaou, M., Meas, T., Delgado, J., Vilas-Boas, F., Paraskevaidis, I., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.098 · Cited by 58
“anemia, renal dysfunction) [3–4,10,14,24–32].”
Butler, J., Ezekowitz, J. A., Collins, S. P., Givertz, M. M., Teerlink, J. R., Walsh, M. N., Albert, N. M., Canary, C. A. W., Carson, P. E., Colvin, M. M., et al. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.02.005 · Cited by 63
“2%) in AfricanAmerican Heart Failure Trial (A-HeFT) had NYHA Class II symptoms.(38) Thus, in African Americans, aldosterone antagonists may be used as add-on therapy in NYHA Class II patients after ACE inhibitors and b-blockers, followed by hydralazine and isosorbide dinitrate in patients who remain symptomatic.”
MethodSelf-citationSacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction
Mann, D. L., Greene, S. J., Givertz, M. M., Vader, J. M., Starling, R. C., Ambrosy, A. P., Shah, P. M., McNulty, S. E., Mahr, C., Gupta, D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.05.005 · Cited by 57
“A-HeFT (23) 1,050 H-I vs placebo LVEF #35% NYHA functional class III–IV 10 months Composite score of death, first hospitalization for heart failure and QOL (MLWHQ) H-I 0.”
Lipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Serban, M.-C., Rysz, J., Voroneanu, L., & Covic, A. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 56
“an ACE inhibitor or ARB [96–99, 106, 108, 109].”
Alolga, R. N., Fan, Y., Chen, Z., Liu, L.-W., Zhao, Y.-J., Li, J., Chen, Y., Lai, M.-D., Li, P., & Qi, L.-W. (2016) · Scientific Reports · doi:10.1038/srep27671 · Cited by 57
Nebivolol: A Third-Generation β-Adrenergic Blocker
Veverka, A., Nuzum, D. S., & Jolly, J. L. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g708 · Cited by 61
Eliminating Healthcare Disparities in America
Williams, R. A. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-485-8 · Cited by 57
Müllens, W., Abrahams, Z., Francis, G. S., Sokos, G. G., Starling, R. C., Young, J. B., Taylor, D. O., & Tang, W. H. W. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.12.028 · Cited by 56
Cox, Z. L., & Lenihan, D. J. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.05.007 · Cited by 56
Nitrate-Induced Toxicity and Preconditioning
Gori, T., & Parker, J. D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.019 · Cited by 60
Pulmonary Hypertension Associated With Advanced Systolic Heart Failure
Shao, Z., Wang, Z., Shrestha, K. L., Thakur, A., Borowski, A. G., Sweet, W. E., Thomas, J. D., Moravec, C. S., Hazen, S. L., & Tang, W. H. W. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.022 · Cited by 59
Conceptualizing Race in Research
Corbie-Smith, G., Henderson, G., Blumenthal, C., Dorrance, J., & Estroff, S. (2008) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31470-x · Cited by 54
Cohn, J. N., McInnes, G. T., & Shepherd, A. M. (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00507.x · Cited by 53
“It has also been combined with isosorbide dinitrate to serve as an antioxidant to help sustain the effect of chronic nitrate therapy for heart failure (HF).(5)”
MethodSelf-citationThe Palliative Care in Heart Failure Trial: Rationale and design
Mentz, R. J., Tulsky, J. A., Granger, B. B., Anstrom, K. J., Adams, P. A., Dodson, G. C., Fiuzat, M., Johnson, K. S., Patel, C. B., Steinhauser, K. E., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.018 · Cited by 53
Heart Failure: A Class Review of Pharmacotherapy.
Shah, A. A., Gandhi, D., Srivastava, S., Shah, K. J., & Mansukhani, R. P. (2017) · PubMed · Cited by 75
Fudim, M., Ponikowski, P. P., Burkhoff, D., Dunlap, M. E., Sobotka, P. A., Molinger, J., Patel, M. R., Felker, G. M., Hernandez, A. F., Litwin, S. E., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2196 · Cited by 56
Docherty, K. F., Ogunniyi, M. O., Anand, I. S., Desai, A. S., Díez, M., Howlett, J. G., Nicolau, J. C., O’Meara, E., Verma, S., Inzucchi, S. E., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.08.006 · Cited by 54
Targeting Nitric Oxide With Drug Therapy
Mason, R. P., & Cockcroft, J. R. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.06041.x · Cited by 59
Cardiovascular Disease in the Elderly
Jackson, C. F., & WENGER, N. K. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.05.003 · Cited by 78
The Vulnerable Phase of Heart Failure
Gracia, E. A., Singh, P., Collins, S. P., Chioncel, O. D., Pang, P. S., & Butler, J. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000794 · Cited by 54
Bibbins-Domingo, K. B., & Fernández, A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-1-200701020-00009 · Cited by 62
“The FDA approval of BiDil was based on the results of the African American Heart Failure Trial (A-HeFT) (11), a randomized, controlled trial of BiDil added to standard therapy for self-identified black patients with heart failure.”
MethodApplication of Adaptive Designs – a Review
Bauer, P., & Einfalt, J. (2006) · Biometrical Journal · doi:10.1002/bimj.200510204 · Cited by 54
“A two-armed, randomized, double blind, placebo-controlled multi-centre clinical trial (Taylor et al., 2004) has been performed to examine whether a therapy provides benefit in a subgroup previously noted to have a favourable response to this therapy.”
BackgroundMetabolomic Profiles and Heart Failure Risk in Black Adults: Insights From the Jackson Heart Study
Tahir, U. A., Katz, D. H., Zhao, T., Ngo, D., Cruz, D. E., Robbins, J., Chen, Z., Peterson, B. D., Benson, M. D., Shi, X. D., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007275 · Cited by 55
Sandhu, A. T., Kohsaka, S., Turakhia, M. P., Lewis, E. F., & Heidenreich, P. A. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.4585 · Cited by 53
Donahue, M., Marchuk, D. A., & Rockman, H. A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.062 · Cited by 56
Selim, A. M., Mazurek, J. A., Iqbal, M., Wang, D., Negassa, A., & Zolty, R. (2015) · Clinical Cardiology · doi:10.1002/clc.22372 · Cited by 53
Angus, D. C., Linde-Zwirble, W. T., Tam, S. W., Ghali, J. K., Sabolinski, M. L., Villagra, V. G., Winkelmayer, W. C., & Worcel, M. (2005) · Circulation · doi:10.1161/circulationaha.105.563882 · Cited by 52
Self-citationLewis, E. F., Claggett, B., Shah, A. M., Liu, J., Shah, S. J., Anand, I., O’Meara, E., Sweitzer, N. K., Rouleau, J. L., Fang, J. C., et al. (2018) · Circulation: Heart Failure · doi:10.1161/circheartfailure.117.004457 · Cited by 52
Huerta, S., Baay-Guzman, G. J., González-Bonilla, C. R., Livingston, E. H., Huerta‐Yépez, S., & Bonavida, B. (2008) · Nitric Oxide · doi:10.1016/j.niox.2008.11.006 · Cited by 52
Evans, W. R. H., Meslin, E. M., Kai, J., & Qureshi, N. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040418 · Cited by 53
“Although this has not been widely utilised to date, pharmaceutical companies and government research funders could use this opportunity to revisit “old drugs” for targeted personalised therapy in specific subgroups [130].”
BackgroundDigoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Val‐HeFT)
Butler, J., Anand, I. S., Kuskowski, M. A., Rector, T. S., Carson, P. E., Cohn, J. N., & for the Val‐HeFT Investigators (2010) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2010.00161.x · Cited by 50
Self-citationColvin, M. M., Sweitzer, N. K., Albert, N. M., Krishnamani, R., Rich, M. W., Stough, W. G., Walsh, M. N., Canary, C. A. W., Allen, L. A., Bonnell, M. R., et al. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.05.013 · Cited by 54
Self-citationPrevention, Diagnosis, and Treatment of Hypertensive Heart Disease
Georgiopoulou, V. V., Kalogeropoulos, A. P., Raggi, P., & Butler, J. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.07.005 · Cited by 59
Acute Decompensated Heart Failure: Treatments and Challenges
Greenberg, B. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0130 · Cited by 54
Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 54
(2008), G. D. T. D. L. E. P. E. D. Y. T. D. L. I. C. A. Y. C., & Desarrollada en colaboración con la Heart Failure Association (HFA) de la ESC y aprobada por la European Society of Intensive Care Medicine (ESICM) (2008) · Revista Española de Cardiología · doi:10.1016/s0300-8932(08)75740-3 · Cited by 83
Anand, I. S., Rector, T. S., Kuskowski, M., Thomas, S., Holwerda, N. J., & Cohn, J. N. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.107.736975 · Cited by 51
Self-citationNarrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials
Yan, A. T.-K., Yan, R. T., & Liu, P. P. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-2-200501180-00013 · Cited by 52
Lapu-Bula, R., & Ofili, E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.12.014 · Cited by 53
A Review of the Ethnic Differences in Breast Cancer
Bowen, R., Stebbing, J., & Jones, L. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.935 · Cited by 50
Hypertensive heart failure: patient characteristics, treatment, and outcomes
Peacock, W. F., Amin, A., Granger, C. B., Pollack, C. V., Levy, P. D., Nowak, R. M., Kleinschmidt, K., Varon, J., Wyman, A. S., & Gore, J. M. (2010) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2010.03.022 · Cited by 50
Racial Differences in Incident Heart Failure During Antihypertensive Therapy
Okin, P. M., Kjeldsen, S. E., Dahlöf, B., & Devereux, R. B. (2011) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.960112 · Cited by 50
Psychiatric genetics – the new era: genetic research and some clinical implications
Prathikanti, S., & Weinberger, D. R. (2005) · British Medical Bulletin · doi:10.1093/bmb/ldh055 · Cited by 51
Mathews, L. M., Ding, N., Mok, Y., Shin, J., Crews, D. C., Rosamond, W. D., Newton, A., Chang, P. P., Ndumele, C. E., Coresh, J., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024057 · Cited by 54
Nitrate therapy and nitrate tolerance in patients with coronary artery disease
Münzel, T. F., & Gori, T. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.12.008 · Cited by 55
“Several more recent reports presented evidence why favorable interactions between hydralazine and the organic nitrate ISDN have been demonstrated in patients with severe heart failure in the Veterans Heart Failure Trials [35] and in the African-American Heart Failure Trial (A-HeFT) [36 ].”
BackgroundDebating the Cause of Health Disparities: Implications for Bioethics and Racial Equality
Roberts, D. E. (2012) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180112000059 · Cited by 54
“BiDil had been tested in the AfricanAmerican Heart Failure Trial, or A-HeFT, launched in 2001.(26) A-HeFT enrolled 1,050 subjects suffering from advanced heart failure, all self-identified African Americans.”
Nine things to remember about human genome diversity
Barbujani, G., Ghirotto, S., & Tassi, F. (2013) · Tissue Antigens · doi:10.1111/tan.12165 · Cited by 52
Race, Common Genetic Variation, and Therapeutic Response Disparities in Heart Failure
Taylor, M. R. G., Sun, A. Y., Davis, G. W., Fiuzat, M., Liggett, S. B., & Bristow, M. R. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.06.010 · Cited by 49
Self-citationAmbrosy, A. P., Gheorghiade, M., Chioncel, O. D., Mentz, R. J., & Butler, J. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0221-9 · Cited by 49
A Randomized Pilot Study of Aortic Waveform Guided Therapy in Chronic Heart Failure
Borlaug, B. A., Olson, T. P., Mohamed, S. A., Melenovský, V., Sorrell, V. L., Noonan, K., Lin, G., & Redfield, M. M. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000745 · Cited by 48
Konstam, M. A. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.05.037 · Cited by 50
Neprilysin Inhibition — A Novel Therapy for Heart Failure
Jessup, M. L. (2014) · New England Journal of Medicine · doi:10.1056/nejme1409898 · Cited by 48
The Marketization of Identity Politics
Bliss, C. (2013) · Sociology · doi:10.1177/0038038513495604 · Cited by 52
“…the US FDA approved the fixed-dose combination of a generic antihypertensive and vasodilator solely for use in people of African descent, after a blacks-only randomized clinical trial demonstrated a 43 percent relative one-year mortality decrease in their research subjects (Taylor et al., 2004).”
BackgroundTurgeon, R. D., Barry, A. R., Hawkins, N. M., & Ellis, U. M. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2141 · Cited by 53
Most Important Articles on Cardiovascular Disease Among Racial and Ethnic Minorities
Mody, P. S., Gupta, A., Bikdeli, B., Lampropulos, J. F., & Dharmarajan, K. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.967638 · Cited by 49
Genes, Race, and Population: Avoiding a Collision of Categories
Kahn, J. (2006) · American Journal of Public Health · doi:10.2105/ajph.2005.067926 · Cited by 55
Impact of gender on statin efficacy
Dale, K. M., Coleman, C. I., Shah, S. A., Patel, A. A., Kluger, J., & Michael White, C. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167516 · Cited by 47
Baseline differences in the HF-ACTION trial by sex
Piña, I. L., Kokkinos, P. F., Kao, A. C., Bittner, V., Saval, M., Clare, B., Goldberg, L. R., Johnson, M. R., Swank, A. M., Ventura, H. O., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.012 · Cited by 50
“Similarly the AHeFT study enrolled 40% women, but these had Class III symptoms primarily.(26)”
MethodDuster, T. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60320-1 · Cited by 47
Unequitable Heart Failure Therapy for Black, Hispanic and American-Indian Patients
Ilonze, O. J., Free, K., & Breathett, K. K. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.02 · Cited by 46
Yancy, C. W., Fonarow, G. C., Albert, N. M., Curtis, A. B., Stough, W. G., Gheorghiade, M., Heywood, J. T., McBride, M. L., Mehra, M. R., O’Connor, C. M., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.681 · Cited by 46
Self-citationGannett, L. (2010) · Synthese · doi:10.1007/s11229-010-9788-1 · Cited by 46
“After the New England Journal of Medicine published results of the African American Heart Failure Trial (A-HeFT) (Taylor et al. 2004), which showed that the combination of the nitric acid donor isosorbide dinatrate and the antioxidant and vasodilator hydralazine—marketed as BiDil by NitroMed,…”
ResultManagement of patients with non-ischaemic cardiomyopathy
Wu, A. H. (2007) · Heart · doi:10.1136/hrt.2005.085761 · Cited by 49
“In addition, the recent African American Heart Failure Trial (A-HeFT) demonstrated that the addition of hydralazine and isosorbide dinitrate to standard heart failure treatment in blacks with severe heart failure (New York Heart Association (NYHA) functional class III or IV) resulted in a 43% reduction in all-cause mo…”
ResultInfluentialZamani, P. L., Akers, S. R., Soto‐Calderon, H., Beraun, M., Koppula, M. R., Varakantam, S., Rawat, D., Shiva‐Kumar, P., Haines, P. G., Chittams, J. L., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004262 · Cited by 51
Cardio-Oncology Preventive Care: Racial and Ethnic Disparities
Prasad, P., Branch, M. E., Asemota, D. E., Elsayed, R., Addison, D., & Brown, S.-A. N. (2020) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-020-00650-8 · Cited by 48
Al‐Mohammad, A., & Mant, J. (2011) · Heart · doi:10.1136/hrt.2010.214999 · Cited by 49
“Thus, their use became limited largely to those intolerant to ACEIs (and later to ARBs), until the impact of race on response to ACEIs became recognised(26) and the subsequent AHEFTstudy showed that patients with symptoms of moderate to severe heart failure of African-Caribbean origin derived further survival benefit…”
BackgroundDavenport, A., Anker, S. D., Mebazaa, A., Palazzuoli, A., Vescovo, G., Bellomo, R., Ponikowski, P. P., Anand, I. S., Aspromonte, N., Bagshaw, S. M., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq252 · Cited by 49
“In symptomatic patients unable to tolerate ACEIs/ARBs, a combination of hydralazine and nitrates may be an alternative [76].”
BackgroundCardiovascular risk factors in minorities
LaRosa, J. C., & Brown, C. D. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.041 · Cited by 50
Camenzind, E., Wijns, W. C., Mauri, L., Boersma, E. H., Parikh, K. H., Kurowski, V., Gao, R., Bode, C., Greenwood, J. P., Gershlick, A., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.10.002 · Cited by 49
Medication adherence in heart failure
Hauptman, P. J. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9020-7 · Cited by 53
“At the same time, based on results from randomized, placebocontrolled trials, advances in medical therapies such as angiotensin-converting enzyme (ACE) inhibitors [2–4], selected angiotensin receptor blockers [5], selected betaadrenergic antagonists (beta-blockers) [6–10], aldosterone antagonists (spironolactone and e…”
BackgroundPacker, M., Pitt, B., Rouleau, J. L., Swedberg, K. B., DeMets, D. L., & Fisher, L. D. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.03.003 · Cited by 47
Wilson, R. M., Silva, D. S. D., Sato, K., Izumiya, Y., & Sam, F. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.134932 · Cited by 50
Molecular Imaging of Human ACE-1 Expression in Transgenic Rats
Dilsizian, V., Zynda, T. K., Petrov, A. D., Ohshima, S., Tahara, N., Haider, N., Donohue, A. M., Aras, Ö., Femia, F. J., Hillier, S., et al. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2011.10.008 · Cited by 45
Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure
Vardeny, O., Cavallari, L. H., Claggett, B. L., Desai, A. S., Anand, I. S., Rossignol, P., Zannad, F. M., Pitt, B., & Solomon, S. D. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000530 · Cited by 49
Chen, A., Wright, H., Itana, H., Elahi, M., Igun, A., Soon, G. G., Pariser, A., & Fadiran, E. O. (2017) · Journal of Women s Health · doi:10.1089/jwh.2016.6272 · Cited by 44
“More recently, studies looking at the combination of isosorbide dinitrate and hydralazine in patients with advanced heart failure demonstrated increased survival in Black/African American patients.(17,18) Collection of race and ethnicity data is encouraged for FDAregulated products in the 2016 guidance, Collection of…”
BackgroundThe African American Heart Failure Trial: A Clinical Trial Update
Taylor, A. L. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.033 · Cited by 44
Self-citationRich, M. W. (2006) · Medical Clinics of North America · doi:10.1016/j.mcna.2006.05.012 · Cited by 48
Pharmacogenetics, Pharmacogenomics and Personalized Medicine: Are We There Yet?
Davies, S. M. (2006) · Hematology · doi:10.1182/asheducation-2006.1.111 · Cited by 44
“Hematology 2006 115 proval was granted based on a randomized study of BiDil in heart failure in black patients that showed a survival advantage compared with placebo; previous studies had failed to show benefit in whites.(37) A new US patent was granted specifically for BiDil use in black patients, although previous p…”
Lynch, J., Bevan, J. L., Achter, P., Harris, T. M., & Condit, C. M. (2008) · New Genetics and Society · doi:10.1080/14636770701843634 · Cited by 49
Gill, P. S., Calvert, M., Davis, R., Davies, M. K., Freemantle, N., & Lip, G. Y. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026710 · Cited by 43
“[14,15,16] Further a large primary care based study in the UK, the Echocardiographic Heart of England Screening (ECHOES) study, reported that the prevalence of symptomatic left ventricular systolic dysfunction (LVSD) in a predominantly White population aged 45 and older was 0.”
Background
Metadata
- Authors
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N.
- Affiliations
- University of Minnesota (US)
- United States Department of Veterans Affairs (US)
- The University of Texas Southwestern Medical Center (US)
- Veterans Health Administration (US)
- Xavier University of Louisiana (US)
- Association of Black Cardiologists (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2049-2057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140023412
- Cited by
- 1,773
- References
- 61
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 43 · 2023: 67 · 2022: 68 · 2021: 70 · 2020: 76 · 2019: 53 · 2018: 58 · 2017: 90 · 2016: 78 · 2015: 79 · 2014: 76 · 2013: 78 · 2012: 97
- FWCI
- 84.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- isosorbide dinitrate, hydralazine, advanced heart failure, Black patients, fixed-dose combination, mortality, heart failure hospitalization, quality of life, dilated ventricles
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Quality of Life, Vasodilator Agents, Survival Analysis, Treatment Outcome, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.